Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

IMPAKT Breast Cancer Conference 2013 /
Biomarker analyses in emerging data from PI3K/AKT/mTOR programme clinical trials

2nd - 4th May 2013

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 16.05.13
Views: 5075
Rating:

Dr Anna Vivancos - Vall d´Hebron Institute of Oncology, Barcelona, Spain

ecancer reporter Peter Goodwin talks to Dr Ana Vivancos at the 2013 IMPAKT meeting in Brussels about her research in to enrolement strategies in Phase I clinical trials.

Dr Vivancos offers advice on the assessment of different mutations and what biomarkers are currently being looked at. Being able to more properly profile the molecular characetirstics of a tumour can lead to improvement of clinical trials and the best therapy for the patient.

Dr Vivancos encourages clinicians to integrate genomics in to their every day practice.

ecancer's filming at IMPAKT has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation